Traders should monitor upcoming clinical catalysts, OP-3136 data in Q2 2026 and OPERA-01 top-line readout in fall 2026, as key value inflection points. The strengthened balance sheet supports operations into 2027, reducing near-term dilution risk.
OLMA drugs
OLMA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $16.60entry
- T+1 · 8mo ago −9.31%α −9.58% · $15.06
- T+5 · 8mo ago −15.84%α −13.80% · $13.97
- T+20 · 7mo ago −1.81%α −5.59% · $16.30
- T+60 · 5mo ago −40.00%α −50.48% · $9.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Olema Oncology reported financial results for 2025, showing increased net losses due to higher R&D spending on late-stage trials for palazestrant and early development of OP-3136. The company raised $218.5 million in a follow-on offering, ending the year with $505.4 million in cash. Key catalysts ahead include top-line data from the Phase 3 OPERA-01 trial in fall 2026 and initial clinical results for OP-3136 in Q2 2026.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $162.5 million, up from $129.5 million in 2024, driven by increased R&D spending.
- GAAP R&D expenses rose to $157.7 million in 2025 from $124.5 million in 2024, including a $10M milestone payment (vs. $5M in 2024).
- Company raised $218.5 million in gross proceeds from a public offering, ending 2025 with $505.4 million in cash and marketable securities.
- Top-line data from Phase 3 OPERA-01 trial expected in fall 2026; initial OP-3136 data expected Q2 2026.
- No revenue generated; company remains pre-commercial with no product sales.
Financial Impact
Increased annual net loss by $33 million YoY; cash position increased by $71.3 million to $505.4 million after offering.
Risk Factors
- Clinical trial setbacks could materially impact valuation, as the company is entirely dependent on development-stage assets.
- Continued losses and future capital raises may lead to shareholder dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256109 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers